The FDA has approved RHA Redensity Eye, a specialized hyaluronic acid (HA) dermal filler from Revance and Teoxane, for the correction of moderate to severe volume loss and hollowing under the eyes in adults aged 22 and older. It's only the second HA filler specifically cleared for the infraorbital (undereye) area, giving clinicians a new on-label option for one of the most technically demanding areas of the face to treat.

The approval was backed by a multicenter, randomized 52-week study showing that 93% of participants saw improvement at 3 months, with results lasting up to 12 months without touch-ups. The filler's formulation is designed to adapt to the delicate dynamics of the undereye region, and its safety profile showed no severe treatment-related adverse events during the study period.

Key Takeaways:

• The trial enrolled ~183 treated subjects — too small to statistically rule out rare but serious vascular occlusion events, estimated at 0.07%–0.3% incidence with HA fillers
• The 52-week follow-up window may be too short to capture delayed complications like chronic edema or inflammatory nodules, which can appear years post-treatment
• Clinicians should interpret "no late-onset adverse events" as a limitation of trial design, not a definitive safety finding

Why it matters: This approval broadens the toolkit for a highly requested aesthetic concern, but experts urge a measured read of the safety data — the trial was not designed to detect rare or delayed complications specific to this sensitive anatomic zone.